Literature DB >> 24306496

Checklist for standardized reporting of drug-drug interaction management guidelines.

Annemieke Floor-Schreudering1, Arjen F J Geerts, Jeffrey K Aronson, Marcel L Bouvy, Robin E Ferner, Peter A G M De Smet.   

Abstract

PURPOSE: Inconsistencies and omissions in drug-drug interaction (DDI) management guidelines may lead to harm and suboptimal therapy. The purpose of this study was to define a checklist for DDI management guidelines to help developers produce high-quality guidelines that will support healthcare providers in clinical practice.
METHODS: We carried out a two-round Delphi process with an international panel of healthcare providers, most of whom are pharmacists involved in providing DDI information, in order to select those items that should be addressed in DDI management guidelines (including grading systems that could be used).
RESULTS: Twenty-three panellists reached consensus on 19 items in two main domains. These were consolidated into a checklist of 15 elements for standardized reporting in management guidelines. For each element a description is provided to specify what information should be documented in that specific element.
CONCLUSIONS: It was possible to reach a broad consensus on which relevant items should be included in a checklist for the development of DDI management guidelines.

Mesh:

Year:  2013        PMID: 24306496     DOI: 10.1007/s00228-013-1612-7

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  27 in total

1.  Practice guidelines developed by specialty societies: the need for a critical appraisal.

Authors:  R Grilli; N Magrini; A Penna; G Mura; A Liberati
Journal:  Lancet       Date:  2000-01-08       Impact factor: 79.321

2.  Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: the AGREE project.

Authors: 
Journal:  Qual Saf Health Care       Date:  2003-02

3.  Requirements for a successful implementation of drug interaction information systems in general practice: results of a questionnaire survey in Germany.

Authors:  Verena Bergk; Christiane Gasse; Rainer Schnell; Walter E Haefeli
Journal:  Eur J Clin Pharmacol       Date:  2004-09-04       Impact factor: 2.953

4.  The quality of information on monitoring for haematological adverse drug reactions.

Authors:  R E Ferner; Jamie Coleman; Munir Pirmohamed; Simon A Constable; Andrew Rouse
Journal:  Br J Clin Pharmacol       Date:  2005-10       Impact factor: 4.335

5.  Comparative assessment of four drug interaction compendia.

Authors:  Agnes I Vitry
Journal:  Br J Clin Pharmacol       Date:  2006-12-07       Impact factor: 4.335

6.  Compliance with national guidelines for the management of drug-drug interactions in Dutch community pharmacies.

Authors:  Henk Buurma; Tom Schalekamp; Antoine C G Egberts; Peter A G M De Smet
Journal:  Ann Pharmacother       Date:  2007-10-30       Impact factor: 3.154

Review 7.  Clinically significant drug-drug interactions between oral anticancer agents and nonanticancer agents: profiling and comparison of two drug compendia.

Authors:  Chen-May Wong; Yu Ko; Alexandre Chan
Journal:  Ann Pharmacother       Date:  2008-11-25       Impact factor: 3.154

8.  SFINX-a drug-drug interaction database designed for clinical decision support systems.

Authors:  Ylva Böttiger; Kari Laine; Marine L Andersson; Tuomas Korhonen; Björn Molin; Marie-Louise Ovesjö; Tuire Tirkkonen; Anders Rane; Lars L Gustafsson; Birgit Eiermann
Journal:  Eur J Clin Pharmacol       Date:  2009-02-11       Impact factor: 2.953

9.  GRADE: an emerging consensus on rating quality of evidence and strength of recommendations.

Authors:  Gordon H Guyatt; Andrew D Oxman; Gunn E Vist; Regina Kunz; Yngve Falck-Ytter; Pablo Alonso-Coello; Holger J Schünemann
Journal:  BMJ       Date:  2008-04-26

10.  Identification of serious drug-drug interactions: results of the partnership to prevent drug-drug interactions.

Authors:  Daniel C Malone; Jacob Abarca; Philip D Hansten; Amy J Grizzle; Edward P Armstrong; Robin C Van Bergen; Babette S Duncan-Edgar; Steven L Solomon; Richard B Lipton
Journal:  J Am Pharm Assoc (2003)       Date:  2004 Mar-Apr
View more
  8 in total

1.  Consensus recommendations for systematic evaluation of drug-drug interaction evidence for clinical decision support.

Authors:  Richard T Scheife; Lisa E Hines; Richard D Boyce; Sophie P Chung; Jeremiah D Momper; Christine D Sommer; Darrell R Abernethy; John R Horn; Stephen J Sklar; Samantha K Wong; Gretchen Jones; Mary L Brown; Amy J Grizzle; Susan Comes; Tricia Lee Wilkins; Clarissa Borst; Michael A Wittie; Daniel C Malone
Journal:  Drug Saf       Date:  2015-02       Impact factor: 5.606

2.  Recommendations for selecting drug-drug interactions for clinical decision support.

Authors:  Hugh Tilson; Lisa E Hines; Gerald McEvoy; David M Weinstein; Philip D Hansten; Karl Matuszewski; Marianne le Comte; Stefanie Higby-Baker; Joseph T Hanlon; Lynn Pezzullo; Kathleen Vieson; Amy L Helwig; Shiew-Mei Huang; Anthony Perre; David W Bates; John Poikonen; Michael A Wittie; Amy J Grizzle; Mary Brown; Daniel C Malone
Journal:  Am J Health Syst Pharm       Date:  2016-04-15       Impact factor: 2.637

Review 3.  Evaluating the safety and dosing of drugs in patients with liver cirrhosis by literature review and expert opinion.

Authors:  Rianne A Weersink; Margriet Bouma; David M Burger; Joost P H Drenth; Nicole G M Hunfeld; Minke Kranenborg; Margje H Monster-Simons; Sandra A W van Putten; Herold J Metselaar; Katja Taxis; Sander D Borgsteede
Journal:  BMJ Open       Date:  2016-10-12       Impact factor: 2.692

4.  The Development of Practice Recommendations for Drug-Disease Interactions by Literature Review and Expert Opinion.

Authors:  Justine M Z van Tongeren; S Froukje Harkes-Idzinga; Heleen van der Sijs; Roya Atiqi; Bart J F van den Bemt; L Willem Draijer; Deline Hiel; Adrian Kerremans; Bart Kremers; Marc de Leeuw; Marleen V Olthoff; T Kim-Loan Pham; Ricky Valentijn-Robertz; Kayan Tsoi; Iris Wichers; Maaike de Wit; Sander D Borgsteede
Journal:  Front Pharmacol       Date:  2020-05-15       Impact factor: 5.810

5.  Quality Indicators of Pharmaceutical Care for Integrative Healthcare: A Scoping Review of Indicators Developed Using the Delphi Technique.

Authors:  Ramzi Shawahna
Journal:  Evid Based Complement Alternat Med       Date:  2020-03-19       Impact factor: 2.629

Review 6.  Understanding and preventing drug-drug and drug-gene interactions.

Authors:  Cara Tannenbaum; Nancy L Sheehan
Journal:  Expert Rev Clin Pharmacol       Date:  2014-04-19       Impact factor: 5.045

7.  Preferences of Patients and Pharmacists with Regard to the Management of Drug-Drug Interactions: A Choice-Based Conjoint Analysis.

Authors:  Mette Heringa; Annemieke Floor-Schreudering; Hans Wouters; Peter A G M De Smet; Marcel L Bouvy
Journal:  Drug Saf       Date:  2018-02       Impact factor: 5.606

8.  Evaluation of drug information resources for drug-ethanol and drug-tobacco interactions.

Authors:  Robert D Beckett; Curtis D Stump; Megan A Dyer
Journal:  J Med Libr Assoc       Date:  2019-01-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.